<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1561">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05140837</url>
  </required_header>
  <id_info>
    <org_study_id>CHESS2106</org_study_id>
    <nct_id>NCT05140837</nct_id>
  </id_info>
  <brief_title>Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106)</brief_title>
  <official_title>Early Diagnosis and Timely Treatment of Cirrhotic Patients With Minimal Hepatic Encephalopathy (CHESS-NCRCID 2106)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hepatopancreatobiliary Surgery Institute of Gansu Province</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Ditan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chongqing Public Health Medical Treatment Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mengchao Hepatobiliary Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Zhuang Autonomous Region People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen Third People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou people's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Union Hospital, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Hainan Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third Affiliated Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ganzhou Fifth People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Baotou Medical College</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ningxia Medical University General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Fourth People's Hospital of Qinghai Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xi'an High-tech Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 10th People's Hospital affiliated to Tongji University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Taiyuan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xichang People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Third Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Third People's Hospital of Tibet Autonomous Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinjiang Autonomous Region People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second People's Hospital of Yunnan Province</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hangzhou Xixi hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hepatopancreatobiliary Surgery Institute of Gansu Province</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic encephalopathy (HE) is a common complication of cirrhosis, which seriously damages&#xD;
      the life quality of patients. As the disease progresses, 50-80% of patients with cirrhosis&#xD;
      develop HE. Minimal hepatic encephalopathy (MHE) is a manifestation of HE, in which the&#xD;
      patient usually has no obvious clinical symptoms and can only be detected by&#xD;
      neuropsychological testing. Early identification and timely treatment are the keys to improve&#xD;
      the prognosis of HE, and the diagnosis of MHE are the priority in the process of the disease&#xD;
      intervention. Guidelines in many countries suggest that MHE does not recommend routine&#xD;
      treatment. However, patients with cirrhosis usually have complex clinical complications, so&#xD;
      whether timely treatment should be taken remains to be explored. The purpose of this study is&#xD;
      to investigate the incidence of MHE in cirrhotic patients, and to establish a real-world&#xD;
      cohort for further study on drug therapy and efficacy evaluation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the 2017 Global Burden of Disease study, there are 10.6 million patients with&#xD;
      decompensated cirrhosis and 112 million patients with compensated cirrhosis worldwide. From&#xD;
      1990 to 2016, the number of patients with cirrhosis and chronic liver disease in China has&#xD;
      increased from nearly 7 million (6833 300) to nearly 12 million (11 869 600), and the&#xD;
      prevalence of all age groups increased by 44%. Hepatic encephalopathy (HE) is a common&#xD;
      complication of cirrhosis, which seriously damages the life quality of patients. As the&#xD;
      disease progresses, 50-80% of patients with cirrhosis develop HE. Minimal hepatic&#xD;
      encephalopathy (MHE) is a manifestation of HE, in which the patient usually has no obvious&#xD;
      clinical symptoms and can only be detected by neuropsychological testing. Early&#xD;
      identification and timely treatment are the keys to improve the prognosis of HE, and the&#xD;
      diagnosis of MHE are the priority in the process of the disease intervention. Guidelines in&#xD;
      many countries suggest that MHE does not recommend routine treatment. However, patients with&#xD;
      cirrhosis usually have complex clinical complications, so whether timely treatment should be&#xD;
      taken remains to be explored. The purpose of this study is to investigate the incidence of&#xD;
      MHE in cirrhotic patients, and to establish a real-world cohort for further study on drug&#xD;
      therapy and efficacy evaluation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 21, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psychometric hepatic encephalopathy score (PHES)</measure>
    <time_frame>1 year</time_frame>
    <description>The PHES is a battery of neuropsychological tests used in the diagnosis of minimal hepatic encephalopathy (MHE). The sum of scores for PHES ranges between +5 and -15. Patients with cirrhosis having a PHES score of &lt;-4 SD are considered to have MHE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical decompensation and death</measure>
    <time_frame>2 year</time_frame>
    <description>Clinically evident decompensating events (specifically ascites, variceal hemorrhage).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EuroQol Five Dimensions Questionnaire (EQ5D)</measure>
    <time_frame>2 year</time_frame>
    <description>EQ5D is used to evaluate the quality of life. EQ-5D consists of two main parts: Descriptive System and Visual Analogue Scale. Five dimensions are used to describe the health state: Mobility, self-care, Usual Activities, Pain/Discomfort, Anxiety/Depression. A scale ranges from 0 to 100, with 0 representing &quot;your worst imagined health&quot; and 100 &quot;your best imagined health.&quot; Self-rated information from respondents can be used as a quantitative indicator of health outcomes.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">10000</enrollment>
  <condition>Hepatic Encephalopathy</condition>
  <condition>Cirrhosis</condition>
  <arm_group>
    <arm_group_label>cross-sectional study</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>real-world cohort study</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Psychometric hepatic encephalopathy score &amp; Stroop test</intervention_name>
    <description>MHE was assessed according to neuropsychological methods. Psychometric hepatic encephalopathy score include number connection test (NCT), digit-symbol test (DST), line-tracing test (LTT) and serial dotting test (SDT). Stroop test can assess psychomotor speed and cognitive flexibility by recording the interference response time between recognizing color fields and writing color names.</description>
    <arm_group_label>cross-sectional study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug therapy</intervention_name>
    <description>Real-world cohort study. The outcomes were examined and registered, so as to evaluate the relationship between therapeutic effects and health outcomes. Psychometric hepatic encephalopathy score and quality of life scale were measured at 3, 6, 12, 18 and 24 months of follow-up.</description>
    <arm_group_label>real-world cohort study</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cirrhosis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age 18-65 years;&#xD;
&#xD;
          2. confirmed cirrhosis based on clinical or pathological criteria;&#xD;
&#xD;
          3. no history of grade 1-4 hepatic encephalopathy;&#xD;
&#xD;
          4. with written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. with other neurological or mental diseases (such as Alzheimer's disease, Parkinson's&#xD;
             disease, etc.);&#xD;
&#xD;
          2. with alcohol or drug addiction and unstable vital signs;&#xD;
&#xD;
          3. with liver cancer or other malignant tumors;&#xD;
&#xD;
          4. fail to comply with psychological tests;&#xD;
&#xD;
          5. incomplete data collection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fu-Sheng Wang, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Clinical Research Center for Infectious Diseases</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiaolong Qi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>LanZhou University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jun-Liang Fu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Clinical Research Center for Infectious Diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiaolong Qi</last_name>
    <phone>8618588602600</phone>
    <email>qixiaolong@vip.163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yufeng Gao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Ditan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wen Xie, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing Public Health Medical Treatment Center</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiangbo Chi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>MengChao Hepatobiliary Hospital of Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yongyi Zeng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Liting Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen Third People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangxi Zhuang Autonomous Region People's Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guizhou Provincial People's Hospital</name>
      <address>
        <city>Guiyang</city>
        <state>Guizhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Hainan Medical College</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Weizhong Yang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third Affiliated Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Caiyan Zhao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shuchen Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Provincial People's Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jia Shang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College, Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xin Zheng, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yan Huang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Baotou Medical College</name>
      <address>
        <city>Baotou</city>
        <state>Inner Mongolia</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tong Dang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu People's Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ganzhou City Fifth People's Hospital</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guanlin Zhou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bethune First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhongfeng Wang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yiling Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ningxia Medical University General Hospital</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shaoqi Yang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Fourth People's Hospital of Qinghai Province</name>
      <address>
        <city>Xining</city>
        <state>Qinghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongmei Zu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xi'an Hi-tech Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ying Song, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanjing Gao, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The 10th People's Hospital affiliated to Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huixiong Xu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third People's Hospital of Taiyuan</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ying Guo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xichang People's Hospital</name>
      <address>
        <city>Xichang</city>
        <state>Sichuan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huasong Huang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Third Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huiling Xiang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Third People's Hospital of Tibet Autonomous Region</name>
      <address>
        <city>Lhasa</city>
        <state>Tibetan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaosong Yan, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinjiang Autonomous Region People's Hospital</name>
      <address>
        <city>Ürümqi</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yongping Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second People's Hospital of Yunnan Province</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jia Wei, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hangzhou Xixi Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shourong Liu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266. doi: 10.1016/S2468-1253(19)30349-8. Epub 2020 Jan 22.</citation>
    <PMID>31981519</PMID>
  </reference>
  <reference>
    <citation>Li M, Wang ZQ, Zhang L, Zheng H, Liu DW, Zhou MG. Burden of Cirrhosis and Other Chronic Liver Diseases Caused by Specific Etiologies in China, 1990-2016: Findings from the Global Burden of Disease Study 2016. Biomed Environ Sci. 2020 Jan 20;33(1):1-10. doi: 10.3967/bes2020.001.</citation>
    <PMID>32029053</PMID>
  </reference>
  <reference>
    <citation>Xiao J, Wang F, Wong NK, He J, Zhang R, Sun R, Xu Y, Liu Y, Li W, Koike K, He W, You H, Miao Y, Liu X, Meng M, Gao B, Wang H, Li C. Global liver disease burdens and research trends: Analysis from a Chinese perspective. J Hepatol. 2019 Jul;71(1):212-221. doi: 10.1016/j.jhep.2019.03.004. Epub 2019 Mar 12. Review.</citation>
    <PMID>30871980</PMID>
  </reference>
  <reference>
    <citation>Zimmermann M, Reichert AS. Rapid metabolic and bioenergetic adaptations of astrocytes under hyperammonemia - a novel perspective on hepatic encephalopathy. Biol Chem. 2021 Jul 30;402(9):1103-1113. doi: 10.1515/hsz-2021-0172. Print 2021 Aug 26. Review.</citation>
    <PMID>34331848</PMID>
  </reference>
  <reference>
    <citation>Bale A, Pai CG, Shetty S, Balaraju G, Shetty A. Prevalence of and Factors Associated With Minimal Hepatic Encephalopathy in Patients With Cirrhosis of Liver. J Clin Exp Hepatol. 2018 Jun;8(2):156-161. doi: 10.1016/j.jceh.2017.06.005. Epub 2017 Jun 20.</citation>
    <PMID>29892178</PMID>
  </reference>
  <reference>
    <citation>Sharma K, Pant S, Misra S, Dwivedi M, Misra A, Narang S, Tewari R, Bhadoria AS. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. Saudi J Gastroenterol. 2014 Jul-Aug;20(4):225-32. doi: 10.4103/1319-3767.136975.</citation>
    <PMID>25038208</PMID>
  </reference>
  <reference>
    <citation>Cabrera-Pastor A, Llansola M, Montoliu C, Malaguarnera M, Balzano T, Taoro-Gonzalez L, García-García R, Mangas-Losada A, Izquierdo-Altarejos P, Arenas YM, Leone P, Felipo V. Peripheral inflammation induces neuroinflammation that alters neurotransmission and cognitive and motor function in hepatic encephalopathy: Underlying mechanisms and therapeutic implications. Acta Physiol (Oxf). 2019 Jun;226(2):e13270. doi: 10.1111/apha.13270. Epub 2019 Mar 22. Review.</citation>
    <PMID>30830722</PMID>
  </reference>
  <reference>
    <citation>Wang JY, Zhang NP, Chi BR, Mi YQ, Meng LN, Liu YD, Wang JB, Jiang HX, Yang JH, Xu Y, Li X, Xu JM, Zhang G, Zhou XM, Zhuge YZ, Tian DA, Ye J, Liu YL. Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China. World J Gastroenterol. 2013 Aug 14;19(30):4984-91. doi: 10.3748/wjg.v19.i30.4984.</citation>
    <PMID>23946605</PMID>
  </reference>
  <reference>
    <citation>Xu XY, Ding HG, Li WG, Jia JD, Wei L, Duan ZP, Liu YL, Ling-Hu EQ, Zhuang H, Hepatology CSO, Association CM. Chinese guidelines on management of hepatic encephalopathy in cirrhosis. World J Gastroenterol. 2019 Sep 28;25(36):5403-5422. doi: 10.3748/wjg.v25.i36.5403.</citation>
    <PMID>31576089</PMID>
  </reference>
  <reference>
    <citation>Flud CR, Duarte-Rojo A. Prognostic Implications of Minimal/Covert Hepatic Encephalopathy: Large-scale Validation Cohort Studies. J Clin Exp Hepatol. 2019 Jan-Feb;9(1):112-116. doi: 10.1016/j.jceh.2018.04.009. Epub 2018 May 4. Review.</citation>
    <PMID>30765944</PMID>
  </reference>
  <reference>
    <citation>Bajaj JS, Lauridsen M, Tapper EB, Duarte-Rojo A, Rahimi RS, Tandon P, Shawcross DL, Thabut D, Dhiman RK, Romero-Gomez M, Sharma BC, Montagnese S. Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. Am J Gastroenterol. 2020 Jul;115(7):989-1002. doi: 10.14309/ajg.0000000000000603.</citation>
    <PMID>32618647</PMID>
  </reference>
  <reference>
    <citation>Reuter B, Walter K, Bissonnette J, Leise MD, Lai J, Tandon P, Kamath PS, Biggins SW, Rose CF, Wade JB, Bajaj JS. Assessment of the spectrum of hepatic encephalopathy: A multicenter study. Liver Transpl. 2018 May;24(5):587-594. doi: 10.1002/lt.25032.</citation>
    <PMID>29457869</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>November 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2021</study_first_posted>
  <last_update_submitted>November 21, 2021</last_update_submitted>
  <last_update_submitted_qc>November 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hepatopancreatobiliary Surgery Institute of Gansu Province</investigator_affiliation>
    <investigator_full_name>Xiaolong Qi</investigator_full_name>
    <investigator_title>Chief</investigator_title>
  </responsible_party>
  <keyword>Minimal hepatic encephalopathy</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Psychometric hepatic encephalopathy score</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Encephalopathy</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

